Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S0347||SWOG||A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III||Adult CIRB - Late Phase Emphasis||Completed|
|S0421||SWOG||Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0427||SWOG||A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin; with and without Docetaxel; Cisplatin; and 5-FluorouracilInduction Chemotherapy; in Patients with Advanced Oropharyngeal Squamous Cell Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0500||SWOG||A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment||Adult CIRB - Late Phase Emphasis||Completed|
|S0502||SWOG||A Phase III Randomized Study of Imatinib; with or without Bevacizumab (NSC-704865); in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT #00324987||Adult CIRB - Late Phase Emphasis||Completed|
|S0518||SWOG||Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced; Poor Prognosis Carcinoid Patients||Adult CIRB - Late Phase Emphasis||Completed|
|S0521||SWOG||A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL); Phase III||Adult CIRB - Late Phase Emphasis||Completed|
|S0600||SWOG||Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX||Adult CIRB - Late Phase Emphasis||Completed|
|S0777||SWOG||A Randomized Phase III Trial of CC-5013 (Lenalidomide; NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341; NSC-681239); Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction; in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0819||SWOG||A Randomized; Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|